Volume: 1 Issue: 1
Year: 2024, Page: 31-33, Doi: https://doi.org/10.71325/ajjms.v1i1.18
Received: Dec. 21, 2024 Accepted: Dec. 23, 2024 Published: Dec. 30, 2024
Bleomycin is an antineoplastic drug used to treat various types of cancer. It can cause pulmonary toxicity (PT) with different patterns on chest computed tomography (CT), including diffuse alveolar injury, organized pneumonia, nonspecific interstitial pneumonia, and bronchiolitis. The exact mechanism of PT remains unclear, but it is related to the generation of active bleomycin radicals in the absence of oxygen. Currently, the only effective treatment for PT is timely administration of corticosteroids to prevent severe respiratory failure and fibrosis. A case of a patient with stage IIIB Hodgkin's lymphoma who experienced clinical deterioration attributed to the toxic effects of bleomycin is presented. The patient's chemotherapy regimen was changed, and the AVD regimen was continued without bleomycin, along with oral steroid treatment for four weeks. After seven weeks, the patient's symptoms improved significantly, and imaging revealed improvement.
Keywords: Bleomycin, Pulmonary toxicity, Hodgkin lymphoma, Traction bronchiolectasis
Azambuja E, Fleck JF, Batista RG, Barreto SSM. Bleomycin lung toxicity: who are the patients with increased risk? Pulmonary Pharmacology & Therapeutics. 2005;18(5):363–366. Available from: https://doi.org/10.1016/j.pupt.2005.01.007
Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617–624. Available from: https://doi.org/10.1378/chest.120.2.617
Lazo JS, Merrill WW, Pham ET, Lynch TJ, Mccallister JD, Ingbar DH. Bleomycin hydrolase activity in pulmonary cells. Journal of Pharmacology and Experimental Therapeutics. 1984;231(3):583–588. Available from: https://pubmed.ncbi.nlm.nih.gov/6209387/
Lam MSH. The need for routine bleomycin test dosing in the 21st century. Annals of Pharmacotherapy. 2005;39(11):1897–1902. Available from: https://pubmed.ncbi.nlm.nih.gov/16219896/
Yagoda A, Mukherji B, Young C, Etcubanas E, Lamonte C, Smith JR, et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Annals of Internal Medicine. 1972;77(6):861–870. Available from: https://doi.org/10.7326/0003-4819-77-6-861
Bond DA, Dotson E, Awan FT, Baiocchi RA, Blum KA, Maddocks K. Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 2019;19(3):e123–e128. Available from: https://doi.org/10.1016/j.clml.2018.11.020
Reinert T, Baldotto CSdR, Nunes FAP, Scheliga AAdS. Bleomycin-induced lung injury. Journal of Cancer Research. 2013;2013:1–9. Available from: https://doi.org/10.1155/2013/480608
Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clinics in Chest Medicine. 1990;11(1):1–20. Available from: https://pubmed.ncbi.nlm.nih.gov/1691067/
Burger RM, Peisach J, Horwitz SB. Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA. Journal of Biological Chemistry. 1981;256(22):11636–11644. Available from: https://doi.org/10.1016/S0021-9258(19)68452-8
Sridhar S, Kanne JP, Henry TS, Revels JW, Gotway MB, Ketai LH. Medication-induced Pulmonary Injury: A Scenario- and Pattern-based Approach to a Perplexing Problem. Radiographics. 2022;42(1):38–55. Available from: https://doi.org/10.1148/rg.210146
Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. Drug-Induced Interstitial Lung Disease: A Systematic Review. Journal of Clinical Medicine. 2018;7(10):1–30. Available from: https://doi.org/10.3390/jcm7100356
Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology. 2011;258(1):41–56. Available from: https://doi.org/10.1148/radiol.10092129
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics. 1981;30(2):239–245. Available from: https://doi.org/10.1038/clpt.1981.154
Jang H, Park K. Omega-3 and omega-6 polyunsaturated fatty acids and metabolic syndrome: A systematic review and meta-analysis. Clinical Nutrition. 2020;39(3):765–773. Available from: https://doi.org/10.1016/j.clnu.2019.03.032
Robinson LE, Mazurak VC. N-3 polyunsaturated fatty acids: relationship to inflammation in healthy adults and adults exhibiting features of metabolic syndrome. Lipids. 2013;48(4):319–332. Available from: https://doi.org/10.1007/s11745-013-3774-6
Vityala S, Kanteti KP, Vityala Y, Zhumabekova A, Vipin. Effects of supplementation with omega-3 polyunsaturated fatty acids as an adjuvant therapy in the treatment of patients with breast cancer: A systematic review. Archives of Breast Cancer. 2023;10(4):323–330. Available from: https://doi.org/10.32768/abc.2023104323-330
BO, Raggi P. The ketogenic diet: Pros and cons. Atherosclerosis. 2020;292:119–126. Available from: https://doi.org/10.1016/j.atherosclerosis.2019.11.021
Vityala S, Kanteti KP, Abdul HM, Vityala Y, Damineni U, Bellam S, et al. Nutritional treatment with the ketogenic diet in children with refractory epilepsy: a narrative review. Exploration of Neuroscience. 2023;2:245–250. Available from: https://doi.org/10.37349/en.2023.00025
Beck SA, Tisdale MJ. Effect of insulin on weight loss and tumour growth in a cachexia model. British Journal of Cancer. 1989;59(5):677–681. Available from: https://doi.org/10.1038/bjc.1989.140
Tisdale MJ, Brennan RA, Fearon KC. Reduction of weight loss and tumour size in a cachexia model by a high fat diet. British Journal of Cancer. 1987;56(1):39–43. Available from: https://doi.org/10.1038/bjc.1987.149
2024 Published by Laxmi Memorial Education Trust ©. This is an open-access article under CC BY 4.0 license. (https://creativecommons.org/licenses/by/4.0/)
Yethindra Vityala, Sai Praneeth Duvvuri, Krishna Chaitanya Meduri, Manjula Shantaram, Pavani Jaladi. Bleomycin-induced Pulmonary Toxicity in a Patient with Hodgkin Lymphoma: A Case Report. AJ J Med Sci 2024;1(1):31–33